{
  "nctId": "NCT02685293",
  "briefTitle": "Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD",
  "officialTitle": "A Randomized, Phase IIIb, Two-period , Double-blind, Two-treatment, Chronic-dosing (7 Days), Single-center Crossover Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease, Compared With Placebo",
  "protocolDocument": {
    "nctId": "NCT02685293",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2016-09-26",
    "uploadDate": "2019-08-12T14:52",
    "size": 6603384,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02685293/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "CROSSOVER",
  "masking": "TRIPLE",
  "enrollmentInfo": {
    "enrollmentCount": 4,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2016-12-09",
    "completionDate": "2018-06-06",
    "primaryCompletionDate": "2018-06-06",
    "firstSubmitDate": "2016-01-28",
    "firstPostDate": "2016-02-18"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* At least 40 years of age and no older than 80 at Visit 1.\n* Women of non-child bearing potential,or negative serum pregnancy test at Screening, and agrees to acceptable contraceptive methods used consistently and correctly from Screening until 14 days after final visit\n* Evidence of lung hyperinflation\n* Subjects with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)\n* Current or former smokers with a history of at least 10 pack-years of cigarette smoking.\n* Pre- and Post-bronchodilator FEV1/FVC ratio must be \\<0.70\n* Post-bronchodilator FEV1 must be ≥30% to \\<65% predicted normal value, calculated using NHANES III reference equations.\n\nExclusion Criteria:\n\n* Significant diseases or conditions other than COPD which, in the opinion of the Investigator, may put the patient at risk\n* Women who are pregnant or lactating or are planning to become pregnant during the course of the study\n* Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma or other active pulmonary disease\n* Subjects who have been hospitalized due to poorly controlled COPD within 3 months prior to Screening\n* Subjects who have poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to Screening or during the Screening Period\n* Subjects who have clinically significant uncontrolled hypertension.\n* Subjects with symptomatic prostatic hypertrophy that is clinically significant and not adequately controlled with appropriate therapy, in the opinion of the Investigator.\n* Subjects with bladder neck obstruction or urinary retention that is clinically significant in the opinion of the Investigator.\n* Subjects with a calculated creatinine clearance ≤30 mL/minute using Chronic Kidney Disease Epidemiology Collaboration. (CKD-EPI) formula at Screening and on repeat testing prior to Visit 2.\n* Subjects with abnormal liver function tests defined as AST, ALT, or total bilirubin ≥ 1.5 times upper limit of normal at Screening and on repeat testing prior to Visit 2\n* Subjects who have cancer that has not been in complete remission for at least five years.\n* Subjects with a diagnosis of glaucoma, who in the opinion of the Investigator, have not been adequately treated.\n* Subjects with a clinically significant ECG\n* Subjects who were previously enrolled in any previous PT001, PT003, or PT005 study conducted or sponsored by Pearl.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "40 Years",
    "maximumAge": "80 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change From Baseline in Right Ventricular End Diastolic Volume Index (RVEDVi) at 2-3 Hours Post-dose on Day 8",
        "description": "Assessment of right ventricular (RV) volume was performed using magnetic resonance imaging (MRI) using RV end diastolic volume (RVEDV), 2-3 hours after dosing on Day 8 of each treatment period. RVEDV was normalized to body surface area (BSA) to provide the indexed counterpart (RVEDVi). Baseline was defined as the pre-dose value on Day 1 of treatment period 1.",
        "timeFrame": "Baseline and Day 8 of either treatment period 1 or 2, as applicable."
      }
    ],
    "secondary": [
      {
        "measure": "Change From Baseline in Aortic Left Ventricular Stroke Volume (LVSV) at 2-3 Hours Post-dose on Day 8",
        "description": "Assessment of LVSV was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.",
        "timeFrame": "Baseline and Day 8 of either treatment period 1 or 2, as applicable."
      },
      {
        "measure": "Change From Baseline in Right Ventricular Stroke Volume (RVSV) at 2-3 Hours Post-dose on Day 8",
        "description": "Assessment of RVSV, phase contrast from pulmonic valve, was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.",
        "timeFrame": "Baseline and Day 8 of either treatment period 1 or 2, as applicable."
      },
      {
        "measure": "Change From Baseline in Pulmonary Artery Velocity at 2-3 Hours Post-dose on Day 8",
        "description": "Assessment of Pulmonary Artery Velocity was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.",
        "timeFrame": "Baseline and Day 8 of either treatment period 1 or 2, as applicable."
      },
      {
        "measure": "Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVi) at 2-3 Hours Post-dose on Day 8",
        "description": "Assessment of left ventricular (LV) volume was performed using MRI using LV end diastolic volume (LVEDV), 2-3 hours after dosing of Day 8 of each treatment period. LVEDV was normalized to BSA to provide the indexed counterpart (LVEDVi). Baseline was defined as the pre-dose value on Day 1 of treatment period 1.",
        "timeFrame": "Baseline and Day 8 of either treatment period 1 or 2, as applicable."
      },
      {
        "measure": "Change From Baseline in Cardiac Output at 2-3 Hours Post-dose on Day 8",
        "description": "Assessment of cardiac output was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.",
        "timeFrame": "Baseline and Day 8 of either treatment period 1 or 2, as applicable."
      },
      {
        "measure": "Change From Baseline in Pulmonary Vascular Resistance (PVR) at 30 and 60 Minutes Post-dose on Day 8",
        "description": "Assessment of PVR was performed by impedance cardiography at 30 and 60 minutes after dosing on Day 8 of each treatment period. Baseline for was defined as the average of the subject values obtained pre-dose on Day 1 of each treatment period.",
        "timeFrame": "Baseline and Day 8 of either treatment period 1 or 2, as applicable."
      },
      {
        "measure": "Change From Baseline in Pulmonary Artery/Aortic Diameter Ratio (PA:A) at 2-3 Hours Post-dose on Day 8",
        "description": "Assessment of PA:A was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.",
        "timeFrame": "Baseline and Day 8 of either treatment period 1 or 2, as applicable."
      },
      {
        "measure": "Change From Baseline in Left Atrial End Diastolic Volume (LAEDV) at 2-3 Hours Post-dose on Day 8",
        "description": "Assessment of LAEDV was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.",
        "timeFrame": "Baseline and Day 8 of either treatment period 1 or 2, as applicable."
      },
      {
        "measure": "Change From Baseline in Left Atrial End Systolic Volume (LAESV) at 2-3 Hours Post-dose on Day 8",
        "description": "Assessment of LAESV was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.",
        "timeFrame": "Baseline and Day 8 of either treatment period 1 or 2, as applicable."
      },
      {
        "measure": "Change From Baseline in Left Atrial Ejection Fraction (LAEF) at 2-3 Hours Post-dose on Day 8",
        "description": "Assessment of LAEF was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.",
        "timeFrame": "Baseline and Day 8 of either treatment period 1 or 2, as applicable."
      },
      {
        "measure": "Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVi) at 2-3 Hours Post-dose on Day 8",
        "description": "Assessment of LV volume was performed using MRI using LV end systolic volume (LVESV), 2-3 hours after dosing on Day 8 of each treatment period. LVESV was normalized to BSA to provide the indexed counterpart (LVESVi). Baseline was defined as the pre-dose value on Day 1 of treatment period 1.",
        "timeFrame": "Baseline and Day 8 of either treatment period 1 or 2, as applicable."
      },
      {
        "measure": "Change From Baseline in Right Ventricular End Systolic Volume Index (RVESVi) at 2-3 Hours Post-dose on Day 8",
        "description": "Assessment of RV volume was performed using MRI using RV end systolic volume (RVESV), 2-3 hours after dosing on Day 8 of each treatment period. RVESV was normalized to BSA to provide the indexed counterpart (RVESVi). Baseline was defined as the pre-dose value on Day 1 of treatment period 1.",
        "timeFrame": "Baseline and Day 8 of either treatment period 1 or 2, as applicable."
      },
      {
        "measure": "Change From Baseline in Pulsatility Index Aorta (PIAo) at 2-3 Hours Post-dose on Day 8",
        "description": "Assessment of PIAo was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.",
        "timeFrame": "Baseline and Day 8 of either treatment period 1 or 2, as applicable."
      },
      {
        "measure": "Change From Baseline in Pulmonary Artery Pulsatility Index (PAPi) at 2-3 Hours Post-dose on Day 8",
        "description": "Assessment of PAPi was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.",
        "timeFrame": "Baseline and Day 8 of either treatment period 1 or 2, as applicable."
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 14,
      "otherCount": 0,
      "totalCount": 15
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "CROSSOVER"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:26.137Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}